ProPhase Labs, Inc. (PRPH) › Cash & EquivalentsProPhase Labs, Inc. (PRPH) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2008: $11.96M2009: $12.80M2010: $8.23M2011: $5.54M2012: $572.0K2013: $1.64M2014: $2.93M2015: $1.66M2016: $441.0K2017: $3.17M2018: $1.55M2019: $434.0K2020: $6.82M2021: $8.41M2022: $9.11M2023: $1.61M2024: $678.0K2025: $90.0K$90.0K2008Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$90.0K-86.7%2024$678.0K-57.9%2023$1.61M-82.3%2022$9.11M+8.3%2021$8.41M+23.4%2020$6.82M+1470.5%2019$434.0K-72.1%2018$1.55M-51.0%2017$3.17M+619.5%2016$441.0K-73.5%2015$1.66M-43.1%2014$2.93M+78.6%2013$1.64M+186.4%2012$572.0K-89.7%2011$5.54M-32.7%2010$8.23M-35.7%2009$12.80M+7.1%2008$11.96M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share